演題詳細

一般口演 / Oral Session

【E】一般口演 16 (Oral Session 16) :MDS:Clinical Research 3

print

日程
2013年10月11日(金)
時間
10:00 - 11:30
会場
第14会場 / Room No.14 (札幌市教育文化会館 3F 研修室305)
座長・司会
石川 隆之 (Takayuki Ishikawa):1
1:Department of Hematology, Kobe City Medical Center General Hospital, Japan
 
前へ戻る

WT-1 expression level in BM is the great prognostic marker with Revised IPSS

演題番号 : OS-1-78

小林 寿美子 (Sumiko Kobayashi):1,2、上田 恭典 (Yasunori Ueda):2、黒川 峰夫 (Mineo Kurokawa):2、田村 秀人 (Hideto Tamura):2、緒方 清行 (Kiyoyuki Ogata):2、檀 和夫 (Kazuo Dan):2、柴山 浩彦 (Hirohiko Shibayama):2、木原 里香 (Rika Kihara):2、恵美 宣彦 (Nobuhiko Emi):2、泉二 登志子 (Toshiko Motoji):2、佐々木 光 (Ko Sasaki):2、臼杵 憲祐 (Kensuke Usuki):2、小川 啓恭 (Hiroyasu Ogawa):2、佐倉 徹 (Toru Sakura):2、大屋敷 一馬 (Kazuma Ohyashiki):2、小澤 敬也 (Keiya Ozawa):2、今井 陽俊 (Kiyotoshi Imai):2、宮崎 泰司 (Yasushi Miyazaki):2、森田 泰慶 (Yasuyoshi Morita):2、松田 晃 (Akira Matsuda):2、通山 薫 (Kaoru Tohyama):2、角元 慶二 (Keiji Kakumoto):2、古賀 大輔 (Daisuke Koga):2、玉置 広哉 (Hiroya Tamaki):2、三谷 絹子 (Kinuko Mitani):2、直江 知樹 (Tomoki Naoe):2、杉山 治夫 (Haruo Sugiyama):2

1:Dept of Hematology and Rheumatology, Nihon University、2:WT1 mRNA Assay Kit MDS Research Group

 

. It is known new classification named revised IPSS(IPSS-R) as a prognosis in MDS patients in 2012. To investigate the clinical utility of WT1 mRNA expression level including IPSS-R, we studied of 82 MDS patients who provided consent at 17 medical institutions nationwide from Dec. 2008 to Sep. 2009 were enrolled. This is the first big report in Japanese MDS patients with R-IPSS. WT1 mRNA level in PB and BM were measured using the WT1 mRNA assay kit "OTSUKA" (OTSUKA PHARMACEUTICAL CO., LTD). The differences in clinical and demographic data were assessed in the chi-square test and logistic regression analysis. In multivariate Cox proportional hazard regression analysis, five out of fifteen parameters, WBC(P=0.0001), IPSS-R(P=0.0007), blast in PB(P=0.0022), WT1 mRNA level in BM(P=0.0057), sex(P=0.01) were independently associated with survival time, but not ANC(both score and absolute number), Hb, plt, karyotype or other parameters.. The WT-1 mRNA level in BM was positively correlated with the prognosis of MDS stage(we reported this meeting in 2012) and tended to be correlated with advanced risk of IPSS-R and WPSS(we reported this meeting in 2012), therefore it was considered to be a useful prognostic marker for MDS. This assay has a great potential to contribute to more appropriate therapeutic decisions in MDS patients as well as diagnosis and to evaluate the timing of allogeneic transplantation.

前へ戻る